date:Sep 28, 2018
nd patients then stay on a maintenance dose equivalent to about one peanut a day.
Aimmune plans to file for regulatory approval by the end of this year. If it's successful, Baird's Skorney estimates the therapy could draw peak sales in 2025 of $1.3 billion worldwide.
It's not the only new treatment in development, though. On almost a parallel track is French biotech DBV Technologies. It too, delivers a small amount of peanut protein each day, but its treatment has a few significant differences